Iveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'

Cowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.

The analyst commented, "The APLS results could not be more positive for Iveric. The data confirmed the complement pathway thesis, and that Iveric is studying the most advantageous lesions for the maximum chance of Phase III success. Meanwhile, Apellis' results call into question pegcetacoplan’s approvability & the safety is concerning even if approved, especially in light of Zimura’s very clean profile to date. Add here."

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Trump approval at 33%, lowest of his presidency - Reuters/Ipsos
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30